These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 36776840)

  • 1. Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress.
    Perrino M; De Vincenzo F; Cordua N; Borea F; Aliprandi M; Santoro A; Zucali PA
    Front Immunol; 2023; 14():1121557. PubMed ID: 36776840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma.
    Hotta K; Fujimoto N
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32098830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma.
    Metro G; Signorelli D; Pizzutilo EG; Giannetta L; Cerea G; Garaffa M; Friedlaender A; Addeo A; Mandarano M; Bellezza G; Roila F
    Hum Vaccin Immunother; 2021 Sep; 17(9):2972-2980. PubMed ID: 34003722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma.
    Cui W; Popat S
    Drugs; 2021 Jun; 81(9):971-984. PubMed ID: 34106454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Traditional Treatment Approaches and Role of Immunotherapy in Lung Malignancy and Mesothelioma.
    Tamanna MT; Egbune C
    Cancer Treat Res; 2023; 185():79-89. PubMed ID: 37306905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapies.
    Hu ZI; Ghafoor A; Sengupta M; Hassan R
    Cancer; 2021 Apr; 127(7):1010-1020. PubMed ID: 33620732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.
    Haakensen VD; Nowak AK; Ellingsen EB; Farooqi SJ; Bjaanæs MM; Horndalsveen H; Mcculloch T; Grundberg O; Cedres SM; Helland Å
    J Transl Med; 2021 May; 19(1):232. PubMed ID: 34059094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab plus ipilimumab in malignant pleural mesothelioma.
    Travert C; Tomasini P; Greillier L
    Expert Rev Anticancer Ther; 2022 Aug; 22(8):815-822. PubMed ID: 35835722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol.
    Shah R; Klotz LV; Chung I; Feißt M; Schneider MA; Riedel J; Bischoff H; Eichhorn ME; Thomas M
    Clin Lung Cancer; 2021 Mar; 22(2):142-146. PubMed ID: 33158765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma.
    Tagliamento M; Bironzo P; Curcio H; De Luca E; Pignataro D; Rapetti SG; Audisio M; Bertaglia V; Paratore C; Bungaro M; Olmetto E; Artusio E; Reale ML; Zichi C; Capelletto E; Carnio S; Buffoni L; Passiglia F; Novello S; Scagliotti GV; Di Maio M
    Crit Rev Oncol Hematol; 2022 Apr; 172():103639. PubMed ID: 35192932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab for the treatment of unresectable pleural mesothelioma.
    Hotta K; Fujimoto N; Kozuki T; Aoe K; Kiura K
    Expert Opin Biol Ther; 2020 Feb; 20(2):109-114. PubMed ID: 31825692
    [No Abstract]   [Full Text] [Related]  

  • 14. [Advances in predictive biomarkers associated with immune checkpoint inhibitors for tumor therapy].
    Guo R; Li X; Hao M; Liang Y; Wang L; Yang Z
    Sheng Wu Gong Cheng Xue Bao; 2023 Apr; 39(4):1403-1424. PubMed ID: 37154314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.
    Rizzo A; Mollica V; Massari F
    Eur Urol Focus; 2022 Jan; 8(1):152-159. PubMed ID: 33516645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
    Brown LC; Zhu J; Desai K; Kinsey E; Kao C; Lee YH; Pabla S; Labriola MK; Tran J; Dragnev KH; Tafe LJ; Dayyani F; Gupta RT; McCall S; George DJ; Glenn ST; Nesline MK; George S; Zibelman M; Morrison C; Ornstein MC; Zhang T
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36252996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
    Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
    Front Immunol; 2021; 12():646874. PubMed ID: 33927719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Research Progress of Immune Checkpoint Inhibitors 
in Malignant Pleural Mesothelioma].
    Huang Y; Meng Q
    Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):441-446. PubMed ID: 34157803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CheckMate 743: A Glimmer of Hope for Malignant Pleural Mesothelioma.
    Uprety D
    Clin Lung Cancer; 2021 Mar; 22(2):71-73. PubMed ID: 33358660
    [No Abstract]   [Full Text] [Related]  

  • 20. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.